![]() |
市场调查报告书
商品编码
1521201
2024-2032 年自动注射器市场报告(按类型(一次性自动注射器、可重复使用自动注射器)、应用(类风湿关节炎、过敏反应、多发性硬化症等)、最终用户(家庭护理机构、医院和诊所)和地区Autoinjector Market Report by Type (Disposable Autoinjectors, Reusable Autoinjectors), Application (Rheumatoid Arthritis, Anaphylaxis, Multiple Sclerosis, and Others), End User (Home Care Settings, Hospitals and Clinics), and Region 2024-2032 |
IMARC Group年全球自动注射器市场规模达22亿美元。
自动注射器是自我注射装置,有助于透过皮下或肌肉内途径输送药物。它们具有多种优势,例如剂量准确性和提高患者依从性,有助于减少患者的针头恐惧症,减少隐藏针头造成的针刺伤害,并提高医疗保健专业人员的便利性和效率。它们广泛用于紧急情况,例如过敏反应、偏头痛、癫痫持续状态、牛皮癣、糖尿病、多发性硬化症和类风湿性关节炎。因此,自动注射器在全球的医院、诊所和家庭护理中心中得到了广泛的应用。
目前,关节炎、气喘、癌症、慢性阻塞性肺病(COPD)和阿兹海默症的盛行率有所上升。这加上对自行给药药物的需求不断增长,是推动市场的关键因素之一。此外,一些国家的政府正在采取倡议,促进在学校使用自动注射器。再加上个人对自动注射器好处的认识不断提高,正在推动市场的成长。此外,主要市场参与者正在广泛投资于研发(R&D)活动,以开发简单、经济高效且基于新技术的自动注射器,用于治疗类风湿性关节炎和多发性硬化症。除此之外,越来越多地采用标靶疗法来改变癌细胞内的蛋白质并防止肿瘤中新血管的形成,这为行业投资者提供了利润丰厚的成长机会。此外,世界各地蓬勃发展的医疗保健产业正在推动市场的成长。促进成长的其他一些因素包括监管批准数量的增加、技术进步、生物製剂专利到期以及自动注射器通用版本的可用性。
The global autoinjector market market size reached US$ 2.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.4 Billion by 2032, exhibiting a growth rate (CAGR) of 13.9% during 2024-2032.
Autoinjectors are self-injectable devices that help deliver drugs via the subcutaneous or intramuscular route. They offer several advantages, such as dosage accuracy and improved patient compliance, and help reduce needle phobia of patients, lower needlestick injuries resulting from a hidden needle, and increase the convenience and efficiency of healthcare professionals. They are widely used during emergency conditions, such as anaphylaxis, migraine, status epilepticus, psoriasis, diabetes, multiple sclerosis, and rheumatoid arthritis. As a result, autoinjectors find extensive applications in hospitals, clinics, and home care centers across the globe.
At present, there is a rise in the prevalence of arthritis, asthma, cancer, chronic obstructive pulmonary disease (COPD) and Alzheimer's disease. This, along with the growing need for self-administrating medicines, represents one of the key factors driving the market. Moreover, governments of several countries are undertaking initiatives to promote the use of autoinjectors in schools. This, coupled with the increasing awareness among individuals about the benefits of autoinjectors, is propelling the growth of the market. In addition, key market players are extensively investing in research and development (R&D) activities to develop simple, cost-effective, and new technology-based autoinjectors for treating rheumatoid arthritis and multiple sclerosis. Besides this, the rising adoption of targeted therapies to alter proteins within cancer cells and prevent the formation of new blood vessels in the tumor is offering lucrative growth opportunities to industry investors. Additionally, the burgeoning healthcare industry around the world is bolstering the growth of the market. Some of the other factors inducing growth are the increasing number of regulatory approvals, technological advancements, patent expiry of biologics and the availability of generic versions of autoinjectors.
IMARC Group provides an analysis of the key trends in each sub-segment of the global autoinjector market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, application and end user.
Disposable Autoinjectors
Reusable Autoinjectors
Rheumatoid Arthritis
Anaphylaxis
Multiple Sclerosis
Others
Home Care Settings
Hospitals and Clinics
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Antares Pharma Inc., Becton Dickinson and Company, Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, Haselmeier GmbH (Sulzer Ltd.), Johnson & Johnson, Mylan N.V. (Viatris Inc.), Novartis AG, SHL Medical AG, Teva Pharmaceutical Industries Ltd. and Ypsomed Holding AG.